399 related articles for article (PubMed ID: 11711374)
21. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491
[TBL] [Abstract][Full Text] [Related]
22. Quantification of PSA mRNA levels in peripheral blood of patients with localized prostate adenocarcinoma before, during, and after radical prostatectomy by quantitative real-time PCR (qRT-PCR).
Kalfazade N; Kuskucu AM; Karadag S; Sahin S; Aras B; Midilli K; Yilmaz G; Tasci AI
Int Urol Nephrol; 2009; 41(2):273-9. PubMed ID: 18584300
[TBL] [Abstract][Full Text] [Related]
23. Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy.
Ogawa O; Iinuma M; Sato K; Sasaki R; Shimoda N; Satoh S; Kato T
Urol Res; 1999 Aug; 27(4):291-6. PubMed ID: 10460902
[TBL] [Abstract][Full Text] [Related]
24. [Detection of prostate-specific antigen mRNA in preoperative peripheral blood of patients with prostate cancer: relationship to pathological parameters of the surgical specimens].
Iinuma M; Sato K; Ogawa O; Sasaki R; Kato T
Nihon Hinyokika Gakkai Zasshi; 1999 May; 90(5):548-56. PubMed ID: 10386054
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
Ylikoski A; Pettersson K; Nurmi J; Irjala K; Karp M; Lilja H; Lövgren T; Nurmi M
Clin Chem; 2002 Aug; 48(8):1265-71. PubMed ID: 12142383
[TBL] [Abstract][Full Text] [Related]
27. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy.
de Cremoux P; Ravery V; Podgorniak MP; Chevillard S; Toublanc M; Thiounn N; Tatoud R; Delmas V; Calvo T; Boccon-Gibod L
Eur Urol; 1997; 32(1):69-74. PubMed ID: 9266235
[TBL] [Abstract][Full Text] [Related]
28. Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer.
Okegawa T; Yoshioka J; Morita R; Nutahara K; Tsukada Y; Higashihara E
Int J Urol; 1998 Jul; 5(4):349-56. PubMed ID: 9712443
[TBL] [Abstract][Full Text] [Related]
29. Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR.
Moreno JG; O'Hara SM; Long JP; Veltri RW; Ning X; Alexander AA; Gomella LG
Urology; 1997 Apr; 49(4):515-20. PubMed ID: 9111619
[TBL] [Abstract][Full Text] [Related]
30. Reverse transcriptase-polymerase chain reaction for prostate-specific antigen in the molecular staging of pelvic surgical margins after radical prostatectomy.
Straub B; Müller M; Krause H; Goessl C; Schrader M; Heicappell R; Miller K
Urology; 2001 May; 57(5):1006-11. PubMed ID: 11337316
[TBL] [Abstract][Full Text] [Related]
31. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy.
de la Taille A; Olsson CA; Buttyan R; Benson MC; Bagiella E; Cao Y; Burchardt M; Chopin DK; Katz AE
Int J Cancer; 1999 Aug; 84(4):360-4. PubMed ID: 10404086
[TBL] [Abstract][Full Text] [Related]
32. Molecular staging of pelvic surgical margins after radical prostatectomy: comparison of RT-PCR for prostate-specific antigen and telomerase activity.
Straub B; Müller M; Krause H; Goessl C; Schrader M; Heicappell R; Miller K
Oncol Rep; 2002; 9(3):545-9. PubMed ID: 11956625
[TBL] [Abstract][Full Text] [Related]
33. Numeric definition of the clinical performance of the nested reverse transcription-PCR for detection of hematogenous epithelial cells and correction for specific mRNA of non-target cell origin as evaluated for prostate cancer cells.
Schamhart D; Swinnen J; Kurth KH; Westerhof A; Kusters R; Borchers H; Sternberg C
Clin Chem; 2003 Sep; 49(9):1458-66. PubMed ID: 12928226
[TBL] [Abstract][Full Text] [Related]
34. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
[TBL] [Abstract][Full Text] [Related]
35. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy.
Olsson CA; de Vries GM; Raffo AJ; Benson MC; O'Toole K; Cao Y; Buttyan RE; Katz AE
J Urol; 1996 May; 155(5):1557-62. PubMed ID: 8627821
[TBL] [Abstract][Full Text] [Related]
36. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
37. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
Chung JW; Kim HT; Ha YS; Lee EH; Chun SY; Lee CH; Byeon KH; Choi SH; Lee JN; Kim BS; Kim TH; Yoo ES; Yoon GS; Baek MC; Kwon TG
PLoS One; 2021; 16(4):e0250254. PubMed ID: 33901217
[TBL] [Abstract][Full Text] [Related]
39. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
40. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
